Ankoor Shah, MD
Ophthalmology · Houston, TXNPI 1841516895
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,444 of the $13,080 with a category attached, or 79.8%. 16 manufacturers reported payments, led by Ocular Therapeutix, Inc. at 48.2% of the total. Reporting peaked in 2024 at $3,504 and has fallen 81.6% since, to $645 in 2025. Among ophthalmology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 96 payments — averaging $136.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ocular Therapeutix, Inc.$6K
- Bausch & Lomb Americas Inc.$3K
- Regeneron$1K
- Regeneron Healthcare Solutions, Inc.$953
- Novartis$338
- AbbVie$277
- plus $944 from 10 others
What the payments were for
- Consulting fees$10,44480%
- Travel & lodging$3383%
- Food & beverage$2,29818%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ocular Therapeutix, Inc. | 7 | $6,311 |
| Bausch & Lomb Americas Inc. | 2 | $2,989 |
| Regeneron | 1 | $1,269 |
| Regeneron Healthcare Solutions, Inc. | 34 | $953 |
| Novartis | 1 | $338 |
| AbbVie(2 entities) | 12 | $277 |
| Apellis Pharmaceuticals, Inc. | 13 | $250 |
| Genentech USA, Inc. | 8 | $176 |
| Astellas Pharma US Inc | 4 | $130 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $101 |
| Coherus Oncology, Inc. | 3 | $81 |
| Biogen | 4 | $73 |
| Alimera Sciences, Inc. | 3 | $65 |
| Dutch Ophthalmic, USA | 1 | $25 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Amgen | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA$1,269
- BEOVU$338
- Tecnis Multifocal Family of 1-piece IOLS$101
How this compares
$13,080 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 99 | $5,952 |
| ProlensaBromfenac Sodium | 15 | $5,263 |
| Difluprednate | 16 | $1,825 |
| Bromfenac Sodium | 11 | $1,633 |
| MoxifloxacinMoxifloxacin Hcl | 66 | $1,535 |
| Ketorolac Tromethamine | 48 | $992 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $700 |
| Latanoprost | 23 | $345 |
| Brimonidine Tartrate | 28 | $229 |
| Cyclopentolate Hcl | 14 | $184 |
| Timolol Maleate | 20 | $180 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Houston
- John MichelettiHouston$916K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Stephen SladeHouston$530K
- David BrownHouston$514K
- Shaheen KavoussiHouston$480K
- Elvia CansecoHouston$322K
- Bac NguyenHouston$319K
- Douglas KochHouston$308K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.